Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.
The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December. Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Aicha Diba
Investor Relations
Direct : +31 20 240 6100
Main: +31 20 566 7394
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
